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Abstract 
This paper reports the optimization and validation of an analytical method for the 
determination of the residual concentration of the prescription antibiotics 
metronidazole, trimethoprim, sulfamethoxazole, azithromycin, clindamicyn, 
clarithromycin, erythromycin-H2O, roxithromycin and tylosin in wastewater and 
advanced treated wastewater. The method applied was used in a study of removal 
efficiency of these compounds at a full scale operational water reclamation plant 
using microfiltration-reverse osmosis (MF-RO) (Kwinana, Western Australia). The 
analytical procedure involves off-line solid-phase extraction (SPE) followed by liquid 
chromatography - tandem mass spectrometry (LC-MS/MS) operated in multiple 
reaction monitoring mode. Method validation included determination of linearity, 
accuracy, precision, method limits of quantitation (MLQs), reproducibility and matrix 
effect. SPE recoveries were generally higher than 89% for both pre- and post- RO 
water, except for erythromycin which yielded approximately 50% recovery. The 
overall precision of the method was better than 16% RSD (relative standard 
deviation), for all compounds and matrices.  MLQ ranged between 23–53 ng/L and 
2.5–31 ng/L for pre- and post- RO water, respectively. In-house reproducibility 
expressed as RSD was generally better than 10%. Inter-laboratory tests revealed a 
generally good agreement between concentrations of antibiotics reported by all 
participants. Results demonstrate that MF/RO treatment is capable of removing 
antibiotics present at relevant environmental concentration in secondary effluent 
(from the low to-mid ng/L range) to below MLQs (2.5–31 ng/L), and more 
importantly, three to six orders of magnitude below the health guideline values 
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1. Introduction 
 To cope with water shortage, reuse of effluents for direct or indirect potable 
purposes is increasingly becoming a necessity in many countries around the world [1, 
2]. To date, the majority of the secondary treated wastewater produced globally is 
discharged into the environment (i.e. rivers, lakes, oceans) while only a small portion 
is reused. Currently, recycled water derived from secondary treated wastewater is 
mainly used for beneficial purposes other than augmentation of drinking water 
supplies. These applications include agricultural and landscape irrigation, industrial 
processes and toilet flushing; indirect potable reuse applications include replenishing 
of natural sources through Ground Water Recharge (GWR), through Soil Aquifer 
Recharge (SAT)  or through River Bank Filtration (RBF) [2]. 
Examples of successful water recycling projects to augment drinking water supplies 
are Orange County Water District in California [3] and Singapore NEWater [4] which 
are continuously promoting innovative programs to turn wastewater into high quality 
recycled water. The health and environmental impacts of trace chemicals is a key 
issue in recycling treated wastewater for direct/ indirect potable reuse. Lack of 
knowledge of health and environmental risks associated with the presence of 
“chemicals of concern” (COCs) and their removal by advanced treatment processes, 
have, to some extent, hindered the establishment of large reuse schemes in Australia; 
even with the advent of advanced technological treatments such as MF/RO, indirect 
potable reuse (IPR) has been slow to gain public acceptance [5]. Gaining public trust 
in organisations, as well as in the technology, is of vital importance. Scientific studies 
to evaluate treatment processes, serve to build the body of knowledge that is required 
for regulators and decision makers and may eventually lead to increased public 
acceptance of IPR [5]. 
 
To ensure consistently high quality recycled water, a multiple barrier approach is 
generally adopted in water reclamation plants [1, 2, 6]. Barriers can comprise a 
variety of possible processes, including: “source protection” which aims to minimise/ 
avoid COCs entering the wastewater; conventional wastewater treatment, which uses 
denitrification, nitrification and activated sludge treatment to remove suspended solids 
and nutrients from the influent wastewater, but often is not an effective barrier to 
COCs; microfiltration/ultrafiltration (pre-treatment) to remove residual suspended 
solids, colloidal particles and micro-organisms; physical processes such as 
nanofiltration (NF) or reverse osmosis (RO) which provide “tighter filtration” or 
“molecular sieving” for removal of COCs, residual nutrients, salts, micro-organisms 
and viruses; UV disinfection (to ensure that all micro-organisms and viruses are 
inactivated); other chemical treatments such as advanced oxidation processes (AOPs) 
to remove residual COCs. AOPs rely on hydroxyl radicals which are powerful non-
selective oxidizing agents and, in principle, are able to mineralize the residual organic 
carbon into CO2 and H2O. However, because of economic and energy restrictions, 
AOP processes at dosages resulting in complete mineralization of target compounds 
are often not sustainable [7]. In addition, several compounds are not amendable to an 
oxidative attack. Incomplete oxidation of PPCPs may result in the formation of 
oxidation by-products with reduced pharmacological effect compared to the parent 
drug compound. For example, it has been demonstrated that it is possible to reduce 
the estrogenic activity of 17α-ethinylestradiol significantly using O3 and other 
oxidants [7]. Other studies have shown that in nearly all cases elimination of 
antibacterial activity has been achieved following treatment of a number of anti-
infective prescription drugs with O3 [8]. The chemical structures and toxicological 
and pharmacological properties of degradation by-products arising from advanced 
oxidation processes are largely unknown for most pharmaceuticals and personal care 
products (PPCPs) [9, 10] although research in this area is developing (e.g. [7, 11]).  
 Regardless of the extent of tertiary treatment applied to “polish” or “refine” 
the product water, public concern regarding wastewater reuse for indirect potable 
reuse is mainly linked to the residual concentration of virus and inorganic and organic 
micropollutants in the recycled water [1, 2, 6]. The effective removal of such organic 
contaminants by tertiary treatments has been a major challenge in the establishment of 
large water reuse schemes. Pollutants in recycled waters that pose major health 
concerns include heavy metals,  organic compounds with suspected carcinogenic 
properties (e.g. nitrosamines and halogenated disinfection by-products), unregulated 
pharmaceuticals and personal care products (e.g. endocrine disrupting compounds, 
cytostatics and antibiotics) and other unregulated trace organic compounds (i.e. 
plasticizers, surfactants) derived from both domestic and industrial activities [1, 2, 12, 
13]. In the last decade, regulatory agencies have struggled to deal with these 
wastewater-derived contaminants because of (1) their characteristic low residual 
concentrations in secondary/tertiary effluents, (2) a lack of standardized analytical 
protocols and (3) a lack of knowledge of potential health and environmental risks 
associated with their presence [6]. 
The work presented in this paper is part of a larger project to investigate the 
effectiveness of advanced tertiary treatment processes, particularly MF/RO, to treat 
secondary treated wastewater for indirect potable reuse. The city of Perth in Western 
Australia (WA) is facing a future of compromised water supplies and a major 
initiative of the Western Australian State Water Strategy is 30% wastewater reuse by 
2030. Recharge of tertiary treated wastewater to aquifers beneath the Swan Coastal 
Plain including Perth’s major drinking water aquifer, the Gnangara Mound, and re-
extracting that water as source of drinking water, will be an important component of 
achieving this goal. Characterization of contaminants in wastewater pre- and post- 
advanced treatment and an assessment of the health and environmental risks are 
necessary to refine health and environmental regulations and to inform the community 
about the recycled water quality [14, 15]. 
 
 The main objectives of this study were: (1) Develop and validate a multi-
component analytical method for analyses of nitroimidazole, sulfonamide, 
lincosamide and macrolide antibiotics (Table 1) in secondary effluent and post- RO 
treated water based on LC-MS/MS. (2) Provide information on the occurrence of 
target analytes in secondary effluents from WWTPs in Western Australia. (3) Assess 
the efficacy of MF/RO to remove specific antibiotics (4) Provide the first locally 
relevant information to assess whether recycled water is safe under the proposed 
treatment and under Western Australian conditions. 
 
Antibiotics and, in general, PPCPs are not yet considered in drinking water 
quality guidelines in Australia [16] or elsewhere [17], although they are included in 
recently published Australian guidelines for recycled water [18]. Antibiotics are 
known to persist during conventional biological treatment processes and consequently 
many of them have been detected in secondary effluents at measurable concentration 
levels (i.e. [1, 6, 19-28]). Moreover, tertiary treatments (e.g. MF/RO) are not 100% 
efficient in removing organic contaminants [1, 6, 14, 15]. Therefore a robust 
analytical protocol and a comprehensive monitoring plan is required to assess their 
presence in water produced for direct and indirect potable reuse, and to investigate 
their removal during tertiary treatment. 
 
2. Experimental 
2.1. Sampling and sample pre-treatment 
Secondary treated wastewater samples were collected from Beenyup and 
Woodman Point WWTPs which are located respectively on the north-west and south-
west of the city of Perth, WA. Both WWTPs employ classical biological treatment for 
removal of suspended solids, nutrients and phosphorous from raw influent 
wastewater. A large portion of the secondary effluent from Perth’s WWTPs is 
currently being discharged into the Indian Ocean (total volume of secondary effluent 
produced in 2008 was 124 GL). Recently, a small portion of secondary effluent from 
Beenyup and Woodman Point WWTPs has been fed into two water recycling 
facilities, where secondary treated wastewater is further treated using MF/RO. Full 
details of the characteristics of the Kwinana Water Reclamation Plant (KWRP) are 
provided in Busetti et al. [29]. A flowchart of KWRP indicating the sampling points is 
shown in Figure 1, available as supplementary information. The water produced 
(approximately 17 ML/day for KWRP) is re-used as general process water by 
neighbouring industrial facilities, reducing Perth’s total demand for scheme water by 
about 2%. Operational conditions at KWRP were: Dow Filmtec BW30-400-FR RO 
membrane (composite polyamide, 8 inch, spiral wound); recovery: 70%; permeate 
flux: 18 L/m2h; pH feed: 6.1; chemical dosing for chloramination (ammonia, 
hypochlorite) and pH control (sulphuric acid) occur prior to microfiltration. 
The second wastewater facility investigated in this work is located at Beenyup, 
north-west of Perth. This pilot plant comprises the first stage of a larger project 
investigating indirect potable reuse through groundwater replenishment. The pilot 
plant receives approximately 100 kL/day of secondary effluent for MF/RO treatment. 
Operational conditions at Beenyup were: Hydranautics ESPA-2 4040 RO membrane 
(composite polyamide, 4 inch, spiral wound); recovery: 70%; permeate flux: 19.7 
L/m2h; pH feed: 6.5; chloramination and pH control procedures are identical to those 
at the KWRP facility (see above). 
Composite and grab samples were collected pre- and post- RO treatment from 
Woodman Point/KWRP plant on three days over a week-long period 30 May - 7 June 
2007. Twenty-four hour composite samples were taken using an automated ISCO 
4700 refrigerated sampler while grab samples were collected from the relevant stream 
at the time of sampling. Aqueous samples taken from Beenyup WWTP and Beenyup 
RO Pilot plant were used to test the reproducibility of the analytical method and 
sampling procedure. Further details are given in Section 3.3.4. Field and trip blanks 
were also collected on each day of sampling. Samples were preserved with 100 mg/L 
of NaN3, which was added as a solid to the amber glass sample bottles (4 L) prior to 
sampling. Samples were stored at 4 °C until sample extraction, which was typically 
performed within 2–3 weeks of sampling.  
 
2.2. Inter-laboratory trial 
The aqueous samples selected for the inter-laboratory trial included a 
groundwater sample, five secondary treated wastewaters, and three post- RO treated 
waters collected from various locations around the city of Perth. On arrival at the 
CWQRC laboratories, the samples were split in equal portions, packed in 
polystyrene boxes containing ice-packs, to minimise degradation during transit, and 
then forwarded to the other participating laboratories. In the following weeks, up to 
seven antibiotics were measured by the three laboratories. More details are given in 
the section 3.3.6. 
 
2.3. Analytical standards and chemicals 
 Analytical standards metronidazole, sulfamethoxazole, trimethoprim (purity > 
99%) were supplied by Riedel-de Haën (Sydney, Australia). Clarithromycin (purity > 
97.7%) was supplied by United States Pharmacopeia-USP, (Maryland, USA). 
Azythromycin and tylosin tartrate (purity > 95%) were supplied by Fluka (Sydney, 
Australia); clindamycin hydrochloride, roxithromicyn, (purity > 90%) were supplied 
by Sigma-Aldrich (Sydney, Australia). Pseudo erythromycin-A enol ether (dehydro-
erythromycin, purity > 98%) and the deuterated standards [2H4] sulfamethoxazole 
(sulfamethoxazole-d4), [2H9] trimethoprim (trimethoprim-d9), [2H3] clarithromycin 
(clarithromycin-d3) and [2H3] azithromycin (azithromycin-d3) were supplied by 
Toronto Research Chemicals (North York, Canada). Isotope enrichment was > 98% 
for all the deuterated standards. Methanol (MeOH) (ChromAR HPLC grade) was 
purchased from Mallinckrodt (New Jersey, USA); ethyl acetate (EtAc), formic acid 
(purity 99%) was purchased from Ajax FineChem (Sydney, Australia). The ultra pure 
water (H2O) used for laboratory purposes as well as LC mobile phase was purified 
using a IBIS Technology (Perth, Australia) Ion Exchange System followed by Elga 
Purelab Ultra System (Sydney, Australia). Glass fiber filters (GF/F, 0.45 µm) were 
purchased from Whatman (Clifton, USA). Stock solutions (nominal concentration of 
1 µg/µL) were prepared by dissolving a known amount of an analytical standard or a 
surrogate standard in MeOH/H2O (30:70 v:v). The stock solution of clarithromycin 
was prepared in acetone due to its low solubility in MeOH/H2O. Two working 
solutions (nominal concentration 10 ng/µL and 1 ng/µL) containing all the analytical 
standards were prepared freshly for each analytical run by serial dilution of the single 
compound stock solutions. A working solution (nominal concentration 10 ng/µL) 
containing all the deuterated standards was prepared bi-monthly. All the solutions, as 
well as analytical and surrogate standards were kept in a commercial refrigerator at 0–
4 ºC to avoid degradation. 
2.4. Solid-Phase Extraction pre-concentration 
 The solid-phase extraction (SPE) procedure was adapted from Göbel et al. 
[21]. Briefly, secondary effluent samples (250 mL) were filtered through 0.45 µm 
glass fiber filters and then diluted to 500 mL with ultra pure water. Post- RO water 
samples were already subject to microfiltration/reverse osmosis treatment in the water 
recycling facilities, and therefore did not require further filtration. A 500 mL aliquot 
was processed through the SPE cartridges. An appropriate surrogate standard mix 
containing the deuterated standards was also spiked before SPE extraction (typically 
ranging between 25–50 ng/L for post- RO water and 200 ng/L for secondary effluent) 
to determine recoveries and to correct for matrix effects. All SPE pre-concentration 
used Oasis HLB (6mL, 500 mg) cartridges (Oasis, Waters), with an automated Aspec 
XLi extractor (Gilson, Middleton, USA) used for the conditioning, washing, and 
elution steps. SPE conditions are also reported (Table 2). Samples were homogenized 
and then loaded onto the SPE cartridges using three 8-channel off-line peristaltic 
pumps (Gilson) at a flow rate of 3 mL/min. After loading and washing, the cartridges 
were gently dried under vacuum in a manifold system for 20–30 minutes and were 
then stored in a freezer (- 18 ºC). For elution, the cartridges were left to defrost at 
room temperature for 3–4 hours and analytes were then eluted into 12 mL glass test 
tubes. The final extract (ca. 12 mL) was concentrated to near dryness in a dry block 
heater fitted with nitrogen blowdown (Ratek 30D, Victoria, Australia) set at 38 °C. 
Extracts were resuspended in 500 µL of MeOH:H2O (30:70 v:v) and then stored in 
2 mL Teflon-lined screw cap amber glass vials at 4 °C until analysis. 
 
2.5. LC-MS/MS method  
 An Agilent 1100 HPLC system (Palo Alto, USA) equipped with a solvent 
degasser unit, a quaternary pump and a 100 well-plate autosampler was used for the 
chromatographic work. LC separation was achieved with a Phenomenex (Torrance, 
USA) Gemini C18 column (125 mm × 3mm, 3µm) at a flow rate of 150 µL/min. 
Other details on the LC method are given in (Table 3), available as supplementary 
information. The LC was coupled to a Micromass Quattro Ultima Triple Quadrupole 
(Manchester, UK) system fitted with an electrospray interface (ESI) operated in 
positive ion mode. For optimum signal, capillary and cone voltages were 2800V and 
30–45V, respectively.  Other MS tuning parameters are listed in (Table 4). When 
instrument source and optics were perfectly clean, hexapole1, aperture and hexapole2 
generally required low voltages (0.0V, 0.1V and 0.1V respectively); the drop in 
sensitivity observed after some use (i.e. when contamination was starting to adversely 
affect source and hexapoles) was corrected by increasing aperture and hexapole2 
between 0.4-0.8V. Nitrogen and argon were supplied by BOC Gases, Australia. 
Nitrogen gas (cryogenic liquid) was used as both desolvation and nebulizer gas, while 
high purity argon (99.997% purity) was used as collision gas for multiple reaction 
monitoring (MRM) experiments. MRM was preferred over SIM (single ion 
monitoring) or MS scan modes because of the superior advantages offered by this 
technique, including high sensitivity, high selectivity, and the low risk of false 
positives. Through tandem-mass spectrometry experiments (MS/MS), the most 
intense characteristic transitions were identified for each analyte and surrogate 
standard (Table 5). Two transitions were used for each compound, and the MRM ratio 
and retention time (tR) was also monitored over the time. Compounds were generally 
characterised by stable MS/MS fragmentation spectra so that identification of the 
main MRM transitions was very simple. To increase the sensitivity of the analytical 
assay, the MRM transitions were also grouped in five windows based on the tR of each 
analyte. The dwell time of each m/z value monitored was set proportionally to the 
number of transitions in that window (Table 5). The maximum number of transitions 
that could be recorded for each time window was 8, with a dwell time of 100 ms.  
Quantitation was performed using the ratio of the peak areas of the analyte and of 
the surrogate standard (Table 5). An external calibration curve, plotting ratio against 
concentration, was obtained by diluting standards in MeOH:H2O (30:70 v:v). 
Concentrations in the samples were calculated by comparing the peak area ratios of 
the analyte and their correspondent surrogate standard in the SPE extract, to the 
corresponding ratios in the standard solution. Calibration curves (usually up to six 
points in the appropriate concentration range) were acquired at the beginning and at 
the end of each batch of samples.  
Instrumental and/or laboratory contamination were also monitored by regular and 
methodical analysis of injector and procedural blanks (laboratory blanks) as well as 
field and trip blanks collected during sampling. About 33% of the samples processed 
were blanks. In particular, analyses of injector blanks revealed that there was 
significant carry-over between injections of standard solutions and samples. The 
memory effect was more pronounced for high molecular weight macrolide antibiotics 
(i.e. tylosin, roxythromycin, azythromycin, erythromycin-H2O and clarythromycin). 
This problem was eliminated by rinsing the injector needle in the injection port with a 
mixture of MeOH:EtAc (50:50 v:v) for 1 minute before and after each injection. 
Data processing was carried out using MassLynx NT 4.0 software, while data 
quantitation was performed using QuanLynx 4.0. 
 
3. Results and discussion 
3.1. Optimization of electrospray interface (ESI) and tandem-mass spectrometry 
(MS/MS) parameters 
ESI and MS/MS tuning parameters were optimised by continuous infusion of 
standards solutions of antibiotics (10 ng/µL in 50:50 (v:v) MeOH:H2O containing 
0.5% formic acid; infusion flow rate of 5–10 µL/min).  Only the positive ionization 
mode was tested because it has been previously reported in several publications (i.e. 
[1, 19, 21]) that ESI(+) is the preferential ionisation mode for these analytes. The 
intensities of the MRM transitions were optimised by varying cone voltage, which 
controls the introduction of the ions into the ion block, and collision energy, which 
influences the formation of fragments in the collision cell. In addition, the ion energy 
settings in the quadrupoles were tuned to achieve best sensitivity at unit mass 
resolution. Cone voltage did not particularly influence the sensitivity of the analytical 
determination, but collision energy required specific tuning for each analyte to ensure 
maximum sensitivity (Table 5). 
The presence of a considerable percentage of formic acid (0.4 – 1.0 %) in the 
mobile phase ensured that the most intense precursor ion observed was the proton 
adduct [M+H]+. Other characteristic precursor ions such as the sodium adduct 
[M+Na]+ or the sodium-solvent adduct ([M+MeOH+Na]+  were not suitable for 
MS/MS fragmentation even when present in the MS scan spectra because they 
produce very noisy and unstable MS/MS spectra. In general, sodium adducts are very 
sensitive ions in SIM mode (i.e. using single quadrupoles or triple quadrupoles in SIM 
mode) but are not suitable to undergo MS/MS or MRM experiments.  The parent ion 
selected for azythromicyn was the double charged [M+2H]+ at m/ z= 375.3, as it 
resulted in the most abundant species in the MS spectra. For azythromycin, Gross et 
al. [19] selected the single charged species [M+H]+ at m/ z= 749 using similar ESI-
MS instrumentation and mobile phase constituted of acetonitrile, methanol (2:1 v:v) 
and a buffer consisting of ammonium acetate, acetic acid at pH = 4.7. Under the 
mobile phase conditions used here, (H2O and MeOH with high percentages of formic 
acid) only the double charged species was present in the MS spectra for 
azythromycin, highlighting the importance of the mobile phase composition in the 
formation of single and double charged species in ESI.  
  The results of these experiments in terms of fragmentation patterns were 
generally in agreement with those previously reported in the literature (i.e. [1, 19, 
21]). 
 
3.2. Development of the chromatographic separation 
Chromatographic separation of the mixture of antibiotics was initially tested using 
two columns. The first column was a Phenyl-C6 column from Phenomenex (250 X 2 
mm, 5 µm), which showed good performance with analytical standards and simple 
water matrices such as spiked ultra pure water, tap water or post-RO water. However, 
this column was generally not suitable for applications involving more complex 
matrices such as secondary effluents due to frequent peak broadening phenomena. 
The second column tested was a Gemini C18 (150 X 2mm, 3 µm), which showed 
excellent chromatographic performance and was subsequently adopted for validation 
and analysis work on the mixture of antibiotics. 
All the compounds showed very reproducible chromatographic peaks using the 
Gemini C18 column. Only metronidazole showed poor retention (tR metronidazole = 9.20 
min) and occasional peak broadening, especially in secondary treated wastewater 
extracts. 
A LC-MS/MS chromatogram showing the separation and detection of the nine 
analytes of interest is presented in Figure 2. The sample selected was a QC sample, 
consisting of 250 mL of secondary effluent diluted to 500 mL with ultra pure water 
and spiked with 100 ng/L of antibiotics and deuterated standards before being 
processed through SPE.  
 
3.3. Validation of the analytical method 
 Studies concerning instrumental linearity, instrumental detection limits (IDLs), 
peak identification criteria (tR and MRM ratio), accuracy, precision, method limit of 
quantitation (MLQ), in-house reproducibility, matrix effect as well as a round-robin 
test were undertaken to validate the analytical procedure. The results of these studies 
are presented in the following sections. 
 
3.3.1. Instrumental linearity, instrumental detection limits and peak identification 
criteria 
 Calibration curves spanning from 10 ng/mL up to 25000 ng/mL of antibiotics 
were injected into the LC-MS/MS to check linearity ranges.  Depending on the 
ionisation efficiency of each compound, calibration curves showed good linearity in 
the range 125–18750 pg injected (except for metronidazole which showed linearity in 
the range 125–6250 pg injected), typically with R2 values higher than 0.9967 (Table 
6). At higher concentration ranges, the linearity of the ESI response was often lost, 
probably due to the limited excess of charge available on the solvent droplets [30]. An 
estimation of the instrumental detection limits (IDLs) based on multiple injections 
(n=10) of  a 0.05 ng/µL solution is also given. IDLs were in the range 1–27 pg of 
analyte on column. These results were consistent with previous studies [19]. The 
instrumental precision based on repeat consecutive injections (n=10) of a solution at 
0.05 ng/µL was also tested to assess variability of peak retention time (tR) and 
variability of the peak MRM ratio. MRM ratio variability (expressed as relative 
standard deviation, RSD) was generally less than 10% and tR variability was generally 
less than 0.3% (except for metronidazole and trimethoprim, with tR variabilities of 2% 
and 1%, respectively). A methodical monitoring of the MRM ratio of the analyte in 
the calibration curve against the MRM ratio of the analyte in the environmental 
sample is an important consideration to avoid reporting false positive detections. In 
fact, the MRM ratio of a given analyte in the calibration curve must match within 20–
30% the MRM ratio in the sample extracts [31]. If this is not the case, it is likely that 
the analyte of interest is co-eluting with interfering species, thus altering the native 
MRM ratio.   
3.3.2. Solid-phase extraction recoveries: accuracy and precision 
 Studies concerning accuracy and precision of the analytical method were 
undertaken by SPE experiments on blank and spiked aqueous samples. The method 
was validated for both secondary effluent and post-RO water. Accuracy was 
expressed as recovery percentage while precision was expressed as RSD. For most of 
the recovery experiments (Table 7), the concentrations tested in post-RO water were 
10, 50, 100 ng/L (n=5 for each spiking level plus three blanks); in secondary treated 
water concentrations tested were 25, 50, 100 ng/L (n=3 for each spiking level plus 
three blanks). No substantial differences in the recovery of the analytes were observed 
after spiking the water samples with different antibiotic concentrations thus recoveries 
are presented as average values at the different concentration levels tested in this 
work. The average percent recoveries of these spikes were generally greater than 89% 
in post-RO water and greater than 93% in secondary effluent (Table 7), except for 
erythromycin-H2O which showed lower recovery percentages (53±11% and 48±8% in 
pre-RO and post-RO aqueous samples, respectively). Other methods utilising SPE 
pre-concentration have reported similar recovery ranges [19, 21, 25, 26, 32, 33]. The 
precision, expressed as the standard deviation of the recovery experiments, was 
generally acceptable, varying between 6–16% in post-RO water and 7–16% in 
secondary effluent. Recovery values in secondary effluent samples were corrected by 
subtracting the concentration of each analyte in the unspiked samples (average of n=3 
blanks) from the concentration of the analyte determined in the corresponding spiked 
samples. No corrections were made for post-RO samples since none of the antibiotics 
were detected in unspiked post-RO samples. 
 
3.3.3. Method limits of quantitation 
 Low level spiking samples were processed through SPE and the results were 
used to estimate Method Limits of Quantitation (MLQs). MLQs were calculated from 
the concentration equivalent to a signal-to-noise ratio (s/n) of ten [29, 34] by manual 
s/n calculation on unsmoothed chromatograms using peaks of known concentration. 
Average sample based MLQs in post-RO water were calculated from analysis of SPE 
extracts of samples spiked with 10 ng/L and 50 ng/L of antibiotics, and were found to 
be between 2.5 and 31 ng/L (Table 7). Average sample based MLQs in treated 
wastewater, were calculated using a range of spiked secondary effluent samples (50–
100 ng/L), and were on average higher than those reported in post- RO water, ranging 
between 23 and 53 ng/L. Since secondary effluent samples contained considerable 
amounts of antibiotics, the concentration corresponding to MLQ was calculated by 
downscaling the s/n ratio of the peak at the measured concentration and assuming a 
linear correlation through zero[21]. MLQs reported in this work were generally in the 
same order of magnitude to those previously reported in literature [19, 21]. Proposed 
health values were calculated by Department of Health of Western Australia using the 
equation used to formulate the Australian Guidelines for Water Recycling (AGWR) 
[18]. The lowest therapeutic dose from the pharmacopeia, with a safety factor of 100 
for an adult of 70 kg of body weight and assuming 2 litres of water consumption per 
day was used in calculating these values. Health target MLD values were set at 10% 
of the AGWR (Table 7). For both post-RO water and secondary treated effluent, 
sample based MLDs (MLDs = MLQs / 3.33, in Table 7) achieved by the SPE LC-
MS/MS method presented in this work were 3 to 6 orders of magnitude lower than the 
health target MLD values (last column of Table 7).  
These results are comparable with other studies. For example, for the antibiotics 
clarithromycin, erythromycin-H2O, roxithromycin, sulfamethoxazole and 
trimethoprim, Webb et al. [35] reported several orders of magnitude difference 
between daily intake calculated from drinking water sources (<40 ng/day, 2L per day) 
and therapeutic dose (between 150–2000 mg/day). This suggests that the health risks 
from ingestion of antibiotics (or other PPCPs (i.e.[14, 15, 29, 35]) via drinking water 
are minimal. 
 The possibility of chronic exposure of organisms to low levels of antibiotics 
through augmentation of natural water supplies with treated wastewater (i.e. through 
SAT, GWR or RBF) has led to concerns of the development of antibiotic resistance in 
the environment. The minimum concentration of antibiotic which will inhibit the 
growth of the isolated microorganism (MIC, Minimum Inhibitory Concentration) is 
an important factor. For example, MIC factors of single antibiotics (i.e. 
sulfamethoxazole, trimethoprim, erythromycin and clindamycin) for various reference 
bacterial strains (S. Aureus, E. Faecalis and E.Coli) often are in the range 101–103 
µg/L [36]. Thus there are several orders of magnitude of difference between the 
observed concentrations of antibiotics in secondary effluent (as well as post- RO 
treated water) and the observed MIC factors. This would imply low risk of 
development of antibiotic resistance in those organisms. Nevertheless, more than one 
compound belonging to a given class of antibiotic as well as other classes of 
antibiotics (e.g. fluoroquinolones, dihydrofolate reductase inhibitors, tetracyclins, 
beta-lactams, aminoglycosides) characterised by much lower MIC factors (i.e. MICs 
as low as 2 µg/L have been reported for ciprofloxacin [36]) are likely to be present in 
the secondary effluents (i.e. [1, 19, 21, 22, 24, 26, 33, 37]). The combination of these 
antimicrobial agents may well result in synergistic effects, and thus the development 
of antibacterial resistance should not be dismissed. 
 
3.3.4. In-house reproducibility of sampling procedure and SPE LC-MS/MS 
methodology 
 In-house reproducibility of the analytical procedure, including water sampling, 
SPE extraction and LC-MS/MS analysis, was tested by duplicate measurements of 24 
hour composite secondary wastewater and post-RO water samples collected on the 
same day (21 January 2008) at the Beenyup water recycling facility. Results from 
these four samples are reported (Table 8). The reproducibility data from unspiked 
samples is limited to a few analytes in secondary effluent only. All the antibiotics 
tested were below detection in the two post- RO water samples, while metronidazole, 
clindamycin and erythromycin-H2O were below detection in the secondary effluent 
samples. To ensure reproducibility data for all analytes, six additional Quality Control 
(QC) samples were also analysed within the batch of samples. QC samples included 
three ultra pure water spiked with 25 ng/L of antibiotics and three secondary effluent 
samples spiked with 100 ng/L of antibiotics. The results obtained for the QC samples 
are also reported (Table 8). In general, the overall RSD of the sampling procedure and 
analytical determination were lower than 10%, very similar to the SPE precision 
reported from spiked matrices (Tables 7-8).  
 
3.3.5. Matrix effect in secondary effluent samples 
Matrix components present in contaminated water samples are known to be 
responsible for suppressing and, less frequently, for enhancing the absolute analyte 
response. This often results in variable detection limits and, more importantly, 
erroneous quantitative results. Matrix components are thought to alter the analyte 
response mainly by (1) influencing the viscosity and surface tension of the mobile 
phase droplets, thereby reducing solvent evaporation efficiency, (2) competing with 
the analyte to gain or lose a charge in the API source, also limiting the ejection of 
charged ions from the droplets, (3) neutralization in gas phase via deprotonation 
reactions with high gas-phase basicity compounds [30]. Regardless of the strategy 
adopted, matrix effects must be addressed to avoid loss of sensitivity, precision and 
accuracy, which are fundamental aspects of an analytical method. There are several 
different approaches proposed in the literature to correct for matrix effects. These 
include specific sample preparation strategies (e.g. SPE), use of surrogate standards, 
standard addition methods, and dilution of the SPE extracts, as well as the “echo 
peak” technique [19, 30, 38, 39]. Developing specific SPE methods with the intention 
of “eliminating” matrix effects is extremely difficult since the analyte and the 
interferences responsible for the signal suppression often have similar polarity and 
retention on stationary reverse phases. Although mild SPE washing steps (i.e. small 
percentages of polar solvents in ultra pure water) have been shown to enhance LC-MS 
method performance [38], matrix effects cannot be totally eliminated by this means. 
In fact, increasing the percentage of organic solvent in the aqueous SPE washing 
solution with the intent of completely washing away the interferences causing ion 
suppression, usually also results in eluting the analyte of interest, with an overall loss 
of sensitivity. The standard addition method is another useful technique for correcting 
matrix effects, but requires multiple injections of the same sample [1, 19, 29, 38]. 
Alternatively, dilution of the SPE extract is an interesting approach explored by Gross 
et al. [19], especially when a suitable surrogate standard is not available or fails to 
correct for matrix effects. However, this again requires multiple dilutions and multiple 
injections of the same sample, ultimately affecting the sample throughput. Similarly, 
reducing the sample volume injected into the LC-MS system would reduce the 
amount of interfering species suppressing the signal [30]. Nevertheless, the latter two 
techniques may not always be applicable for trace analysis [19, 30, 39]. The “echo-
peak” technique proposed recently [30], involves injection of a standard followed by 
injection of the sample, so that analytes in the standard and in the sample would elute 
in a similar chromatographic region and would be subject to a similar degree of signal 
suppression/enhancement.  
To account and correct for matrix effects in this study we chose to use deuterated 
standards. This approach has proven very reliable [19, 30, 38] since it is likely that the 
analyte and a co-eluting deuterated homologue would be subject to almost identical 
matrix effects. First of all, ion suppression was generally observed for all the 
compounds in secondary effluent extracts, however, matrix effects were automatically 
accounted for in the case of those analytes that were quantified with their 
corresponding deuterated homologue (sulfamethoxazole, azythromycin, trimethoprim 
and clarythromycin (Table 5)). Deuterated homologues were not available for the 
nitroimidazole anti-infective metronidazole and for the macrolide antibiotics tylosin, 
erythromycin-H2O, roxythromycin and clindamycin. Therefore, matrix effects were 
further investigated for these compounds. The deuterated standard chosen for 
metronidazole was sulfamethoxazole-d4, while tylosin, erythromycin-H2O, 
roxythromycin and clindamycin were quantified using clarithromycin-d3. To 
effectively correct for matrix effects, a surrogate standard should elute in the same 
chromatographic region as the target analyte and should show a similar degree of ion-
enhancement/ion suppression. To verify the efficiency of the chosen surrogate 
standards to correct for signal changes due to ion suppression, the peak area to 
concentration ratio of standard calibration curves in 70:30 (v:v) MeOH:H2O were 
compared to those in three different wastewater samples each spiked to a different 
concentration. The spiking concentrations tested were 25, 50 and 100 ng/L of 
antibiotics. Results for metronidazole, roxithromycin and clindamycin are shown in 
Figure 3, available as supplementary information. The calibration lines (equation of 
the line and linearity) for spiked samples showed excellent agreement with those for 
standards in pure solvent, showing that the surrogate standards effectively overcome 
matrix effects. Similar trends were observed also for tylosin and erythromycin-H2O 
(data no shown). Ongoing QC controls (data not shown) using different wastewater 
samples (n=15 over a 12 month period) from various Perth WWTPs confirm that the 
deuterated standards chosen are appropriate to correct for matrix effects. 
3.3.6. Inter-laboratory trial 
 As part of good laboratory practice and method validation for Curtin Water 
Quality Research Centre (CWQRC), a laboratory comparison for the measurement of 
seven antibiotics was organised in May - June 2007. The trial participants were 
CWQRC located in Perth WA, National Measurement Institute (NMI, Sydney NSW), 
and DVGW-Technologiezentrum Wasser (TZW, Karlsruhe, Germany). Seven 
antibiotics were measured by the three laboratories. Only three analytes were 
measurable by all participants. These were erythromycin-H2O, roxithromycin, and 
sulfamethoxazole. The results of the inter-laboratory trial are presented (Table 9). 
NMI and TZW laboratories are randomly named Lab1 and Lab3, while CWQRC was 
Lab2.  There was generally good agreement in the concentrations measured by all 
laboratories, and no significant trends or deviations were evident for most of the 
compounds. The only significant difference was observed for the macrolide 
clarithromycin, where measured concentrations are in disagreement. Unfortunately, 
RSDs associated with sample measurements were not available because the samples 
were not processed in duplicate due to costs associated with shipping and analysing 
the samples.  It is also interesting to note that the antibiotic concentrations in the post- 
RO treated waters and in the groundwater, which is from a relatively pristine 
protected catchment, were reported to be below the detection limits by all 
laboratories. 
 
3.4. Concentrations of antibiotics in pre- and post- RO water and estimation of 
compounds rejection by the MF/RO plant 
  While the presence of a number of classes of human and veterinary antibiotics 
has been reported in previous studies [19, 21-24, 26-28, 33, 37, 40-42] there is a 
significant lack of data concerning their presence in Australian wastewater effluents. 
A comprehensive study on the behaviour of antibiotics during conventional 
wastewater treatment followed by MF/RO filtration for a water recycling facility 
located in Brisbane, Australia was published recently [1]. In the present study, the 
antibiotics sulfamethoxazole, trimethoprim, erythromycin-H2O, roxithromycin 
azithromycin and clarithromycin were detected in all the secondary treated effluents 
(Table 9) while metronidazole and clindamycin were detected only in 40% of the 
samples. Data for tylosin was not available for that specific set of effluent samples. 
Concentration ranges of antibiotics found in secondary effluents from Perth’s 
metropolitan WWTPs compare well with those previously reported from several other 
WWTPs (i.e.[1, 19, 21-24, 26-28, 33, 43, 44], see also Table 10) suggesting that 
dosage and antibiotic classes prescribed are often globally very similar and that 
classical wastewater treatment plants are not effective in achieving complete removal 
of such compounds from raw influent wastewater. Data for metronidazole in 
secondary effluent and post-RO is scarce. 
For comparison, the concentrations of each antibiotic reported by the three 
laboratories (Table 9) have been averaged and compared with the ADWG. Results for 
the most commonly detected antibiotics (i.e. metronidazole, sulfamethoxazole, 
trimethoprim, erythromycin-H2O, clindamycin, roxithromycin and clarithromycin) are 
presented in Figure 4. The concentrations of these compounds measured in secondary 
wastewater effluent were three to four orders of magnitude lower than the suggested 
guidelines for drinking water. In contrast to pre-RO water, antibiotic concentrations in 
post-RO samples were always below detection limits, (MLQs reported were four to 
five order of magnitude lower than suggested guidelines for drinking water), 
suggesting that RO was efficiently removing these antibiotics from secondary treated 
wastewater. Watkinson et al. [1] have reported very small residual concentrations of 
some antibiotics including roxithromycin (med. 10 ng/L, frequency 100%, LOD = 1 
ng/L), trimethoprim (med. 5 ng/L, frequency 100%, LOD = 1 ng/L) and tylosin (med. 
1 ng/L, frequency 100%, LOD = 1 ng/L) in post- MF/RO treated water from the 
Brisbane water recycling facility, with overall removal efficiencies from the liquid 
phase higher than 90%. From our data, removal efficiencies for RO can only be 
estimated because most compounds could not be measured in post-RO water. 
However, using the post-RO water MLQ as upper bound, removal efficiencies ranged 
between > 91–99%. These estimated results compare very well to those calculated or 
predicted for other water recycling plants. For example, Drewes et al. [6] predicted 
and verified high removal (> 90%) for antibiotics such as erythromycin, 
sulfamethozaxole and trimethoprim through RO rejection experiments. Similarly, 
Snyder et al. [20] reported rejection efficiencies of greater than 98% with a MF/RO 
pilot system for the antibiotics erythromycin-H2O, sulfamethoxazole and 
trimethoprim. Further research is currently being conducted to investigate trends in 
concentration and to study the effective rejection properties of RO membranes. 
Additional data from other Perth wastewater treatment plants is being acquired to 
investigate possible antibiotic distribution trends around the Perth metropolitan area.  
4. Conclusions 
 A SPE LC-MS/MS method was developed for the analysis of nine antibiotics 
in pre- and post-RO water samples. Validation data showed good accuracy and 
precision and the LODs achieved easily detected concentrations of antibiotics at levels 
found in secondary wastewater and were suitable for studies of the efficacy of MF/RO 
for further removal of these compounds. Concentration ranges found in secondary 
effluents from Perth WWTPs compare well with data previously published in 
literature. None of the nine antibiotics were detected in any post-RO treated water 
sample analysed, suggesting RO is an effective treatment to reduce concentrations of 
antibiotics in secondary treated effluents. Several orders of magnitude difference was 
observed between MLQs in post-RO and proposed drinking water limit guidelines 
calculated by Western Australian Department of Health suggesting that concerns with 
regards to indirect exposure of antibiotics via recycled water are minimal. Estimated 
RO rejection was generally higher than 91%.  
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7. Figure captions 
Figure 1. Flow chart of Kwinana Water Reclamation Plant (KWRP) indicating the 
sampling points used in this work: Panel 1 (secondary effluent, pre- MF) and Panel 7 
(product water, post- RO). MF= microfiltration; RO= reverse osmosis. 
 
Figure 2. A typical LC-MS/MS chromatogram for separation of nine antibiotics using 
the Phenomenex Gemini C18 column (150 mm × 2mm, 3 µm particle size) at a flow 
rate of 0.15 mL/min. The sample selected was a QC sample, constituted of 250 mL of 
secondary effluent spiked with 100 ng/L of antibiotics before being processed through 
SPE. 
 
Figure 3. Comparison of peak area ratios to concentration ratio for metronidazole 
(surrogate standard: sulfamethoxazole-d4), roxithromycin and clindamycin (surrogate 
standard: clarithromycin-d3), for both standard calibration curves in MeOH:H2O 
70:30 (v/v) and three spiked secondary effluent samples. Curves are almost identical, 
indicating that the surrogate standards chosen were able to correct ion suppression and 
matrix effects although they are not the exact deuterated homologues. 
 
Figure 4. Concentrations of selected antibiotics in pre and post- RO samples 
compared to the Australian Drinking Water Guidelines calculated by Western 
Australian Department of Health using the equation used to formulate the draft 
Australian guidelines for water recycling [18]. Note that none of the antibiotics 
analysed were detected in post- RO water and the values reported in the figure are the 










Table 1. Name, formula, molecular weight, molecular structure, CAS number, class 































































































































































Table2. SPE conditions adopted for enrichment/clean-up of the nine antibiotics 
SPE conditions Solvents and dispensed volumes 
Conditioning 
flow rate = 5 mL/min 
6 mL MeOH:EtAc (1:1, v:v) 
6 mL MeOH with 1% NH4OH (v:v) 
12 mL water (pH = 4, formic acid) 
Loading 
flow rate = 3 mL/min 
500 mL post- RO or 250 mL secondary effluent 
diluted to 500 mL with ultra pure water                        
(pH = 4, formic acid) 
Washing 
flow rate = 5 mL/min 
4.5 mL water with 10% MeOH (v:v) 
12 mL water (pH = 4, formic acid) 
Drying/Storage 20–30 minute at 20 mmHg followed by storage at    - 18 ºC 
Elution* 
flow rate = 1 mL/min 
3 mL + 3 mL MeOH with 1% formic acid (v:v) 
3 mL + 3 mL MeOH:EtAc (1:1, v:v) 
 
*Note: 3 minutes delay is applied between each aliquot dispensed. This ensures that the stationary phase is efficiently soaked 

















Table 3. Liquid chromatographic parameters adopted for the separation of the nine 
antibiotics 
Time [min] Eluent A [%] Eluent B [%] 
0 10 90 
5 10 90 
10 15 85 
15 40 60 
20 60 40 
30 70 30 
32.5 100 0 
55 100 0 
55.1 10 90 
75 10 90 
LC conditions: 
 
Eluent A: MeOH with 1% formic Acid 
Eluent B: H2O with 0.4% formic acid 
Flow rate: 0.15 mL/min 
Column: Gemini C18 (150mm × 2mm, 
3µm) 
Precolumn: Gemini C18 (4mm × 
3mm, 3µm) 
Injected volume: 12.5 µL of post- RO 






















Table 4. General ESI(+) and MS/MS tuning parameters adopted for the detection of 
antibiotics 
ESI-MS tuning parameters Setting 
Capillary voltage (V) 2800 
Cone voltage (V) 30–45 
Hex.1, aperture, hex.2 (V) 0.0, 0.1, 0.1 
Source temperature ( ºC) 130 
Desolvation temperature ( ºC) 325 
N2 cone gas flow  (L/h) 30 
N2 desolvation gas flow  (L/h) 325 
Quad.1 and quad.3 resolution 1 



















Table 5. Precursor and product ions, cone voltage and collision energy values 













Window 1:5.0–15.0  min 








Window 2: 18.0–25.0 min 
















Window 3: 25.1–28.0 min 
































Window 4: 27.0–30.5 min 
















Window 5: 30.0–34.0 min 
































a surrogate standard used for quantitation was sulfamethoxazole-d4 
b surrogate standard used for quantitation was clarithromycin-d3  










Table 6. Linear ranges and regression values typically observed for calibration 
curves; instrumental detection limits (IDLs) estimated at s/n = 3, instrumental 
precision in terms of MRM ratio and tR (average ± RSD) were obtained from repeated 
injections (n=10) of a solution at 0.05 ng/µL of antibiotics 
 
Standard solutions 
Compound Linear range 
tested        
(pg on column) 
R2 
IDL    
s/n=3 
(pg on column) 
MRM 
ratio        
(±RSD%) 
tR            
(±RSD%) 
Metronidazole 125–6250 0.9982 15 3.2±8 9.2±2.0 
Trimethoprim 125–18750 0.9989 6 5.8±10 22.3±1.0 
Sulfamethoxazole 125–18750 0.9982 7.5 1.4±10 26.1±0.3 
Azythromycin 125–18750 0.9997 15 17±6 25.6±0.3 
Clindamycin 125–18750 0.9995 1 2.4±6 27.4±0.2 
Tylosin 125–18750 0.9967 3.5 1.4±9 29.1±0.1 
Erythromycin-H2O 125–18750 0.9997 27 2.2±5 31.0±0.2 
Clarythromycin 125–18750 0.9996 2 2.1±6 31.1±0.2 


















Table 7. Accuracy, precision and MLQs in post- RO and secondary effluent achieved 
with the SPE LC-MS/MS method; target MLD values developed for the project are 
also reported 
 
a n=12, spiked concentration between 10–50 ng/L 
aa n=9, spiked concentration between 100–250 ng/L 
b n=6, spiked concentration between 50–100 ng/L 
bb n=6, spiked concentration 50 ng/L 
c n=6, spiked concentration between 10–50 ng/L 






































(RSD,        
n=9) 
MLQ  









Metronidazole 114 16 15–45 (31) 112 15 25–67 (53) 350000  
Trimethoprim 106 6 5–8 (6.5) 112 11 25–90 (52) 70000  
Sulfamethoxazole 94 6 5–17 (9) 101 12 25–100 (53) 35000  
Azythromycin 100 a 13 a 10–21 (15) 106 aa 16 aa 25–85 (50) 4000  
Clindamycin 112 11 5–12 (8) 93 9 15–40 (23) 300000  
Tylosin 102 b 13 b 5–8.5 (7.5) 100 bb 7 bb 18–50 (27) 1050000  
Erythromycin-H2O 48 
c 8 c 7–20 (10) 53 cc 11 cc 35–50 (45) 35000  
Clarithromycin 97 7 3–20 (7.5) 97 8 10–60 (30) 250000  
Roxithromycin 89 12 1–3.5 (2.5) 95 7 5–85 (32) 150000   
Table 8. Reproducibility of the SPE LC-MS/MS method on real samples (i.e. treated 
wastewater and post-RO water) sampled on the 21 January 2008 from Beenyup water 
treatment plant. QC samples are also included and were a triplicate of secondary 



































Beenyup secondary effluent Beenyup post- RO 
Compound Average (ng/L) 
±RSD 
QC samples: 





 Recovery (%)              
±RSD 
Metronidazole < MLQ 77±10 < MLQ 130±3 
Trimethoprim 216±9 92±3 < MLQ 102±7 
Sulfamethoxazole 304±2 92±2 < MLQ 99±3 
Azythromycin 206±4 125±5 < MLQ 106±6 
Clindamycin < MLQ 80±2 < MLQ 74±4 
Tylosin 21±7 105±6 < MLQ 103± 6 
Erythromycin-H2O < MLQ 63±1 < MLQ 55±3 
Clarithromycin 142±2 105±2 < MLQ 95±5 
Roxithromycin 150±7 92±3 < MLQ 103±8 
Table 9. Inter-laboratory comparison for the analysis of selected antibiotics: aqueous 
samples for the trial were one groundwater sample, five secondary treated wastewater 
samples, and three post- RO treated water samples collected from various locations 



















b Secondary treated effluent 



























Table 10. Concentration of antibiotics in secondary effluent and post- RO samples 















Country References  
Metronidazole < 25–71 < 15 n.a. Australia This study 
170a … … USA [28] 
180 … … USA [27] 
320b … … Germany [33] 
70–310 … … Spain [19] 
86–170 … … Switzerland [21] 
468 2.1 99.5 USA [6] 
80 5 93.7 Australia [1] 
186 < 1 > 99.5 USA [20] 
Trimethoprim 
170–485 < 5 > 98.9 Australia This study 
200a … … USA [28] 
310 … … USA [27] 
400b … … Germany [33] 
< 20–820 … … Spain [19] 
243c … … Canada [24] 
344–352 … … Switzerland [21] 
939 2.0 99.8 USA [6] 
255 < 3 > 98.8 Australia [1] 
90 1.2 98.7 USA [20] 
Sulfamethoxazole 
400–680 < 5 > 99.1 Australia This study 
110–129 … … Switzerland [21] 
50–210 … … Spain [19] Azithromycin 
< 50–160 < 10 n.a. Australia This study 
1 < 1  91 Australia [1] Clindamycin < 45–65 < 5 n.a. Australia This study 
< 5–31 … … Switzerland [23] 
680b … … Germany [33] 
11–21 … … Switzerland [21] 
8c … … Canada [24] 
… … > 90 USA [6] 
140 10 92.8 Australia [1] 
Roxithromycin 
300–390 < 1 > 99.7 Australia This study 
… … > 90 USA [6] 
270a … … USA [28] 
2500b … … Germany [33] 
80c … … Canada [24] 
< 20–199 … … Switzerland [23] 
<6 … … Spain [19] 
54–96 … … Switzerland [21] 
detected detected n.a. Australia [1] 
336 < 1 > 99.7 USA [20] 
Erythromycin-
H2O 
360–930 < 20 > 94.5 Australia This study 
188–374 … … Switzerland [21] 
87c … … Canada [24] 
57–328 … … Switzerland [23] Clarithromycin 
210–290 < 20 > 91.4 Australia This study 
60 … … USA [44] Tylosin 20 1 95 Australia [1] 
a n=10 WWTP effluent samples  
b n=10 WWTP effluent samples 




















































































































































y = 0.6063x - 0.0329
R2 = 0.9998














































Signal Metronidazole in 70:30 H2O:MeOH
Signal Metronidazole in spiked secondary
effluent
Linear (Signal Metronidazole in 70:30 H2O:MeOH)
Linear (Signal Metronidazole in spiked
secondary effluent)  
Clindamycin
y = 0.4932x - 0.0257
R2 = 0.9938






































Signal Clindamycin in 70:30 H2O:MeOH
Signal Clindamycin in spiked secondary effluent
Linear (Signal Clindamycin in 70:30 H2O:MeOH)




y = 1.2188x + 0.0089
R2 = 0.9995







































Signal Roxithromycin in 70:30 H2O:MeOH
Signal Roxithromycin in spiked secondary
effluent
Linear (Signal Roxithromycin in 70:30 H2O:MeOH)
Linear (Signal Roxithromycin in spiked
































































































Secondary treated ef f luent
MLQs in post- RO w ater
Australian Drinking Water
Guidelines
                                                                                                  
 
 
 
 
 
 
 
 
